BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player
BioTheryX is continuing to rake in investor capital, netting a fresh $92 million Series E round on Thursday.
The San Diego-based company noted it will fund at least two specific programs in its announcement: BTX-A51 and BTX-1188. The former, BioTheryX’s lead candidate, is a multi-kinase inhibitor looking at p53 protein modulation in acute myeloid leukemia, myelodysplastic syndrome and solid tumors. BTX-A51 is currently in a Phase I trial for r/r AML.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.